The FDA approved pertuzumab-dpzb (Poherdy) as the first biosimilar for its reference product Perjeta, a monoclonal antibody commonly used in standard regimens for HER2-positive breast cancer. FDA ...

The U.S. Food and Drug Administration (FDA) approved Poherdy (pertuzumab-dpzb) as the first interchangeable biosimilar to ...

Pertuzumab-dpzb is now considered an interchangeable biosimilar to pertuzumab as part of treatment combinations in multiple ...

HR-positive/HER2-negative breast cancer grows with estrogen or progesterone, lacking high HER2 protein levels, making hormone ...

In terms of prognostic risk factors, HER2 positivity, BM surgical resection, and diagnosis after 2014 were associated with ...

The addition of neoadjuvant trastuzumab deruxtecan (T-DXd; Enhertu) significantly improved pathologic complete response (pCR) ...

FDA approves 1st biosimilar to Perjeta, Poherdy, for HER2-positive breast cancer treatment, enabling pharmacy-level substitution under state law.

The agreement with EirGenix grants Sandoz exclusive rights to commercialize proposed biosimilar of pertuzumab for treatment ...

United States will be diagnosed with breast cancer in their lifetime. It is important to know the HER-2 status of the tumor - ...

Oncology teams across West Virginia continue pushing for renewed funding to give patients the emotional strength to keep ...

The DESTINY-Breast11 (DB-11) and DESTINY-Breast05 (DB-05) trials, presented at the European Society for Medical Oncology ...

The EMA’s recommendation follows evidence that the targeted therapy improves progression-free survival in patients whose ...